← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Monoclonal antibodies
vedolizumab
L04AG05
Forms & Strengths
- Intravenous infusion: 300 mg lyophilized powder in a single-dose vial
- Subcutaneous injection: 108 mg/0.68 mL pre-filled syringe or pre-filled pen
Adult Dosing
- Ulcerative Colitis & Crohn's Disease (IV): 300 mg administered at 0, 2, and 6 weeks, then every 8 weeks thereafter
- Ulcerative Colitis & Crohn's Disease (Subcutaneous): 108 mg once every 2 weeks, following at least 2 intravenous doses at weeks 0 and 2
Pediatric Dosing
- Safety and effectiveness in pediatric patients below 18 years of age have not been established
Indications
- Moderately to severely active ulcerative colitis in adults
- Moderately to severely active Crohn's disease in adults
Mechanism of Action
- Humanized monoclonal antibody that specifically binds to the alpha-4 beta-7 integrin
- Inhibits the binding of alpha-4 beta-7 integrin to mucosal addressin cell adhesion molecule-1 (MAdCAM-1)
- Blocks adhesion of memory T-lymphocytes to gut endothelial tissue, reducing gastrointestinal inflammation
Contraindications
- History of hypersensitivity to vedolizumab or any of its excipients
- Active severe infections, such as tuberculosis, sepsis, cytomegalovirus, and listeriosis, until the infection is resolved
Adverse Reactions
- Common: Nasopharyngitis, headache, arthralgia, upper respiratory tract infection, nausea
- Serious: Infusion-related reactions and hypersensitivity reactions, severe infections, progressive multifocal leukoencephalopathy (PML)
- Gastrointestinal: Diarrhea, abdominal pain, gastroenteritis
Drug Interactions
- Live vaccines: Avoid concurrent administration of live vaccines with vedolizumab
- Immunosuppressants: Concomitant use with other systemic immunosuppressants or biologic immunomodulators may increase the risk of infection
Curated Content: Needs Vetting Before Put to Clinical Use